Development of Tc-99m labeled tropanes: TRODAT-1, as a dopamine transporter imaging agent

doi:10.1016/S0969-8051(01)00220-7

Nuclear Medicine and Biology

Volume 28, Issue 5, July 2001, Pages 505-508

https://doi.org/10.1016/S0969-8051(01)00220-7 Get rights and content

Abstract

Advances in the technetium chemistry have significantly enhanced the development of Tc-99m radiopharmaceuticals for clinical use. Efforts in designing novel Tc-99m labeled receptor or site-specific imaging agents using [Tc^vO]⁺³N₂S₂ core have produced useful imaging agents for single photo emission computed tomography (SPECT). The success in developing Tc-99m TRODAT-1 for CNS dopamine transporters (DAT) serves as the first example of Tc-99m site-specific imaging of human brain. New innovative Tc-99m labeled site-specific agents are particularly suitable to develop simple and useful routine diagnostic procedures.

Section snippets

Acknowledgements

Authors would like to thank Mei-Ping Kung, Ph.D. and Laura Cesaro for their assistance in preparing this manuscript, David Mozley, M.D. and Paul Acton, Ph.D. for providing the 3D rendered Tc-99m TRODAT-1/SPECT images and the financial support of DOE (ER-61657) and NIH (NS-24538 and NS-18509).

References (25)

S.R. Choi et al.
An improved kit formulation of a dopamine transporter imaging agent[Tc-99m]TRODAT-1
Nucl. Med. Biol.
(1999)
P.D. Acton et al.
Simplified reference region model for the kinetic analysis of [99mTc]TRODAT-1 binding to dopamine transporters in nonhuman primates using single-photon emission tomography
Eur. J. Nucl. Med.
(1999)
J.L. Baulieu et al.
Effects of the method of drawing regions of interest on the differential diagnosis of extrapyramidal syndromes using 123I-iodolisuride SPET
Nucl. Med. Commun.
(1999)
J. Booij et al.
Practical benefit of [¹²³I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson’s disease
Eur. J. Nucl. Med.
(1997)
J. Booij et al.
Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism
Eur. J. Nucl. Med.
(1999)
S. Dresel, J. Krause, K.-H. Krause, C. LaFougere, K. Brinkbäumer, H.F. Kung, K. Hahn, K. Tatsch, Attention deficit...
W.C. Eckelman et al.
External imaging of cerebral muscarinic acetylcholine receptors
Science
(1984)
A.J. Fischman et al.
Rapid detection of Parkinson’s disease by SPECT with altropanea selective ligand for dopamine transporters
Synapse
(1998)
J.J. Frost et al.
Positron emission tomographic imaging of the dopamine transporter with [¹¹C]-WIN 35,428 reveals marked declines in mild Parkinson’s disease [see comments]
Ann. Neurol.
(1993)
S. Hillier et al.
Radiolabeling of the highly selective DAT ligand, O-¹⁵O5t, with 99mTcchoice of transchelation agent
J. Nucl. Med.
(2000)

A. Hoepping et al.

TROTEC-1a new high-affinity ligand for labeling of the dopamine transporter

J. Med. Chem.

(1998)

S.S. Jurisson et al.

Potential technetium small molecule radiopharmaceuticals

Chem. Rev. (Washington, D.C.)

(1999)

Cited by (50)

An overview: Radiotracers and nano-radiopharmaceuticals for diagnosis of Parkinson's disease
2024, Applied Radiation and Isotopes
Parkinson's disease (PD) is a widespread progressive neurodegenerative disease. Clinical diagnosis approaches are insufficient to provide an early and accurate diagnosis before a substantial of loss of dopaminergic neurons. PET and SPECT can be used for accurate and early diagnosis of PD by using target-specific radiotracers. Additionally, the importance of BBB penetrating targeted nanosystems has increased in recent years. This article reviews targeted radiopharmaceuticals used in clinics and novel nanocarriers for research purposes of PD imaging.
Lanthanide nanoparticles for near-infrared II theranostics
2022, Coordination Chemistry Reviews
Citation Excerpt :
Biomedical imaging plays an significant role in both fundamental scientific researches and clinical theranostic applications [1–10]. Indeed, in the last few decades, the development of biomedical imaging technologies and corresponding contrast agents has resulted in a set of imaging methods in clinical practices, consisting of magnetic resonance imaging (MRI) [11–15], computed tomography (CT) [16–20], single-photo emission computed tomography (SPECT)[21–25] and positron emission tomography (PET) [26–30], allowing legible observation of physiological and pathological changes that deepen the understanding of life-threatening human diseases.Table 1. However, tomography imaging modes (including CT, PET and SPECT) have long suffered from low spatial resolution and involve the use of harmful ionizing radiations, preventing their uses in patients who are vulnerable to the effects of radiation, such as pregnant women and babies.
Fluorescence imaging in the second near-infrared biological window (NIR-II, 1000–1700 nm) presents unparalleled merits of non-invasion, high sensitivity, deeper penetration depth, less destructiveness to biomatrix, and minimized tissue autofluorescence, which has been actively applied in preclinical applications. Among currently available NIR-II fluorescence probes, lanthanide-based nanoparticles show a myriad of merits containing large Stokes shift, sharp emission peaks, and type-determined emissions in a broad spectrum (1000–3000 nm), and thus have aroused a reviving attention for their uses in fluorescence imaging and sensing. Recent advances on both up/down-conversion in precise composition, structure, and morphology control endow lanthanide-based nanoparticles with defined fascinating luminescence profiles in the NIR-II region. In this review, we systematically compare the merits of lanthanide-based nanoparticles with other types of NIR-II probes, highlight cutting-edge progress in the development of lanthanide-based nanoparticles, and showcase their emerging applications in the field of theranostics. Perspectives and challenges on their future development are also discussed.
Organometallic Chemistry of Drugs Based on Technetium and Rhenium
2022, Comprehensive Organometallic Chemistry IV: Volume 1-15
This section reviews progress in bioorganometallic chemistry with rhenium and technetium over the past two decades. It includes general considerations with respect to the concepts for which the compounds of the two elements described here are designed. The more specific subsections focus on the traditional field of receptor targeting with ^99mTc radiopharmaceuticals and molecular imaging agents. More recently, non-radioactive, de novo rhenium complexes have emerged as versatile tools for various applications in life sciences. Progress in this respect is discussed for rhenium alone or in combination with ^99mTc homologs where applicable. Some urgent disease targets such as Alzheimer's disease are given special attention. Future directions, incentives for research, are reviewed throughout. The objective of this section is to not only provide a comprehensive review on organometallic chemistry of rhenium and technetium in the life sciences, but also to give a scope for the field based on recent accomplishments.
Longitudinal changes in the dopamine transporter and cognition in suicide attempters with charcoal burning
2015, Psychiatry Research - Neuroimaging
Citation Excerpt :
We administered two executive function tests, the Wisconsin Card Sorting Test (WCST) and the Color Trails Test (CTT), a culturally fair analog of the Trail Making Test (Shan et al., 2008). Preparation of [99mTc] TRODAT-1 ([2-[[2-[[[3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3,2,1]oct-2-yl]methyl](2-mercaptoethyl)amino]ethyl]amino]ethanethiolato(3-)-N2,N2′,S2,S2′]oxo-[1R-(exo-exo)]-(99m)Tc-technetium) was carried out as previously described (Kung, 2001), with minor modifications (Chou et al., 2007). In brief, it was prepared from a lyophilized kit by adding 1.110 MBq freshly eluted Tc-99-pertechnetate to a 5-ml saline preparation.
Suicide with charcoal burning, which results in carbon monoxide (CO) poisoning, is common in Asia. This study was designed to elucidate associations between changes in the dopamine transporter (DAT) and cognitive function in patients following CO poisoning during a follow-up period of 6 months. Participants comprised 31 healthy controls (HCs) and 21 CO poisoning patients. Each subject underwent single photon emission computed tomography with [^99mTc] TRODAT-1 to measure DAT availability and completed a cognitive battery assessing attention, memory, and executive function. For CO poisoning patients, a second DAT measurement and repeated cognitive evaluations were performed 6 months later. At baseline, DAT availability over bilateral striatum in CO poisoning subjects was significantly lower than in HCs. After 6 months, there was no significant change of DAT availability in CO poisoning patients. CO poisoning patients also had worse cognitive performance in all domains compared with HCs at baseline. After 6 months, most cognitive functions were significantly improved, except for the Wisconsin Card Sorting Test (WCST), a measure of executive function. Interestingly, changes in the WCST were significantly correlated with changes in DAT availability during the 6-month follow-up period. The persistence of reduced DAT availability and its association with impaired performance on the WCST indicate a crucial role of DAT in the recovery of executive function following CO poisoning.
Diagnostic imaging of Alzheimer's disease with copper and technetium complexes
2012, Coordination Chemistry Reviews
Citation Excerpt :
Parkinson's disease is characterised by loss of dopamine neurons in the basal ganglia and substantia nigra. It has been estimated that in each month, about 100 scans using [99mTcVO(TRODAT-1)] are performed in Taiwan [100,101]. Attempts to provide technetium complexes suitable for diagnostic imaging of Aβ plaque burden have generally involved a bifunctional chelate approach, where ligands suitable for technetium are tethered to known plaque binding functional groups such as benzothiazoles and congo-red inspired derivatives.
The most common form of dementia is Alzheimer's disease, a progressive neurodegenerative disease that leads to synaptic failure and neuronal death. This review discusses the development of copper and technetium coordination complexes designed as radiopharmaceuticals to assist in the diagnosis of Alzheimer's disease using positron emission tomography or single photon emission computed tomography. Technetium complexes used to image regional brain perfusion are discussed as well as copper and technetium complexes specifically designed to bind to amyloid-β plaques that are associated with the onset of symptoms of the disease.
Dual-isotope SPECT imaging of striatal dopamine: First episode, drug naïve schizophrenic patients
2008, Schizophrenia Research
The aim of this investigation was to evaluate the usefulness of a dual-isotope SPECT technique to assess simultaneously striatal dopamine binding structures — presynaptic dopamine transporter (DAT) and postsynaptic dopamine D₂ receptor — in first-episode, drug-naive schizophrenic patients compared to healthy control persons. Additionally, relations between radioligand binding to DAT and D₂ and positive symptoms were assessed.
Twenty acutely ill inpatients suffering from a first acute schizophrenic episode and 12 healthy control persons participated in the study. Patients were naïve with respect to neuroleptic or antidepressant medication. A dual-isotope SPECT protocol was performed using combined application of [99mTc]TRODAT-1 and [123I]IBZM. On the day of SPECT, psychopathology was assessed in the patient group by PANSS rating.
In the patient but not in the healthy control group there was a significant correlation between DAT and D₂ receptor availability. Patients with predominant positive symptoms (n = 12) had a significantly higher DAT availability compared to the healthy control group. An inverse correlation between DAT and D₂ availability and the extent of “delusions”, “conceptual disorganization”, and “hallucinatory behaviour” could be demonstrated.
The data obtained with this dual-isotope SPECT technique show a change in interaction between striatal DAT and D₂ receptor in first-episode, never-treated schizophrenic patients. Additionally, an association between dopamine transmission and the core symptoms of the acute psychotic syndrome was found.

View all citing articles on Scopus

View full text

Development of Tc-99m labeled tropanes: TRODAT-1, as a dopamine transporter imaging agent

Abstract

Section snippets

Acknowledgements

Nucl. Med. Biol.

Simplified reference region model for the kinetic analysis of [99mTc]TRODAT-1 binding to dopamine transporters in nonhuman primates using single-photon emission tomography

Eur. J. Nucl. Med.

Effects of the method of drawing regions of interest on the differential diagnosis of extrapyramidal syndromes using 123I-iodolisuride SPET

Nucl. Med. Commun.

Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson’s disease

Eur. J. Nucl. Med.

Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism

Eur. J. Nucl. Med.

External imaging of cerebral muscarinic acetylcholine receptors

Science

Rapid detection of Parkinson’s disease by SPECT with altropanea selective ligand for dopamine transporters

Synapse

Positron emission tomographic imaging of the dopamine transporter with [11C]-WIN 35,428 reveals marked declines in mild Parkinson’s disease [see comments]

Ann. Neurol.

Radiolabeling of the highly selective DAT ligand, O-15O5t, with 99mTcchoice of transchelation agent

J. Nucl. Med.

TROTEC-1a new high-affinity ligand for labeling of the dopamine transporter

J. Med. Chem.

Potential technetium small molecule radiopharmaceuticals

Chem. Rev. (Washington, D.C.)

Practical benefit of [¹²³I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson’s disease

Positron emission tomographic imaging of the dopamine transporter with [¹¹C]-WIN 35,428 reveals marked declines in mild Parkinson’s disease [see comments]

Radiolabeling of the highly selective DAT ligand, O-¹⁵O5t, with 99mTcchoice of transchelation agent